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Abstract: Live attenuated recombinant measles vaccine virus (MV) Edmonston-Zagreb (EZ) strain was evaluated as a 
viral vector to express the ectodomains of fusion protein of respiratory syncytial virus (RSV F) or glycoprotein 350 of 
Epstein-Barr virus (EBV gp350) as candidate vaccines for prophylaxis of RSV and EBV. The glycoprotein gene was 
inserted at the 1
st or the 3
rd position of the measles virus genome and the recombinant viruses were generated. Insertion of 
the foreign gene at the 3
rd position had a minimal impact on viral replication in vitro. RSV F or EBV gp350 protein was 
secreted from infected cells. In cotton rats, EZ-RSV F and EZ-EBV gp350 induced MV- and insert-specific antibody 
responses. In addition, both vaccines also induced insert specific interferon gamma (IFN-) secreting T cell response. EZ-
RSV F protected cotton rats from pulmonary replication of RSV A2 challenge infection. In rhesus macaques, although 
both EZ-RSV F and EZ-EBV gp350 induced MV specific neutralizing antibody responses, only RSV F specific antibody 
response was detected. Thus, the immunogenicity of the foreign antigens delivered by measles vaccine virus is dependent 
on the nature of the insert and the animal models used for vaccine evaluation. 
Keywords: Measles vaccine, Edmonston-Zagreb, RSV F, EBV gp350, Cotton rats, Rhesus monkeys. 
INTRODUCTION 
  Live attenuated viruses have been developed and used to 
help protect humans from various infectious diseases. Live 
attenuated vaccine viruses simulate natural infection and are 
highly immunogenic and effective in inducing both humoral 
and cellular immune responses. Because of their 
demonstrated safety and effectiveness against infectious 
diseases, different live attenuated vaccine viruses have been 
explored as vectors to express heterologous antigens [1]. 
Measles vaccine (MV) strain has a long history of 
demonstrated safety in humans. It induces long lasting 
immunity including antibody and T cell responses [2-4]. 
Aerosol administration of measles vaccine is also being 
developed and has been shown to induce similar or better 
immunogenicity compared to conventional subcutaneous or 
intramuscular vaccination [5, 6]. This aerosol administration 
route may offer advantages in helping to protect individuals 
from mucosal pathogens. 
  The development of reverse genetics for negative 
stranded RNA viruses including measles virus has made it 
possible to explore the utility of the negative stranded RNA 
viruses to deliver foreign antigens. Measles vaccine virus has 
been explored by several laboratories to express foreign 
antigens such as the spike and nucleocapsid proteins of 
SARS coronavirus, HIV gp160, HPV L1 and hepatitis B 
surface antigens [7-10]. The vectored MV induces robust 
antibody and T cell responses against both insert antigens   
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and MV [7-18], making it an attractive option for 
vaccination against measles as well as other infectious 
agents. Although some studies showed that MV could boost 
measles virus immune response in school aged children who 
had previously received measles vaccine [19, 20], the pre-
existing immunity to measles virus may reduce the 
immunogenicity of the vectored measles vaccine [21, 22]. 
Thus, the utility of MV vector in measles seropositive 
population remains to be determined. Several studies 
performed in the early 1980s in developing countries 
revealed that high seroconversion rates were achieved with 
EZ measles vaccine despite the presence of high titer of 
maternal measles virus antibody [23]. Therefore, the EZ 
strain might be immunogenic in populations with histories of 
measles vaccination or preexisting MV immunity. 
  In this study, we explored the use of the EZ vaccine 
strain to deliver viral antigens for prevention of RSV and 
EBV associated diseases. RSV causes severe lower 
respiratory tract illness in infants and the elderly. 
Bronchiolitis from RSV infection in infants is associated 
with recurrent wheezing and asthma in childhood [24]. No 
vaccine is available to prevent morbidity and mortality from 
RSV infection. The surface fusion (F) protein of RSV is a 
major antigenic protein that induces neutralizing antibodies, 
CD8
+ cytotoxic T lymphocytes, and protection against 
subsequent RSV challenge in mice or cotton rats [25]. High 
levels of F neutralizing antibodies are sufficient to protect 
the lower respiratory tract infection [26] and have been used 
for prophylactic purpose in infants. 
  EBV is a gamma herpes virus that causes infectious 
mononucleosis in adolescents [27]. In addition, EBV has 
been associated with certain malignancies including 
Burkitt’s lymphoma, post-transplantation lymphoprolifera-Evaluation of Measles Vaccine Virus as a Vector  The Open Virology Journal, 2012, Volume 6    13 
tive disease, lymphoma and nasopharyngeal carcinoma [28]. 
There is no prophylactic EBV vaccine available. The surface 
glycoprotein gp350, which binds to human CD21 receptor 
on B cells to mediate viral entry, has been identified as a 
protective antigen. The adjuvanted EBV gp350 protein has 
been shown to be efficacious in a randomized phase II study 
in preventing infectious mononucleosis [29]. Here, we report 
the construction of an infectious measles virus by reverse 
genetics system and the insertion of the F protein of 
respiratory syncytial virus or gp350 of EBV into MV virus 
as a separate transcriptional unit. The vectored viruses were 
then evaluated in cotton rats and rhesus macaques for their 
immunogenicity. 
MATERIALS AND METHODS 
 Viruses  and  cells.  RSV A2 strain was obtained from 
ATCC (Manassas, MA). EZ vaccine strain was from Serum 
Institute of India (Pune, India). Vero and HEp-2 cells were 
maintained in Dulbecco’s modified Eagles’s medium 
(Invitrogen, Carlsbad, CA) supplemented with 2% fetal 
bovine serum (FBS), 2mM L-glutamine, and 1% 
penicillin/streptomycin at 37°C with 5% CO2. 
  Construction of Measles vaccine virus rescue system. 
Antigenomic cDNA was synthesized by DNA2.0 (Menlo 
Park, CA) based on the sequence of live attenuated measles 
virus Edmonston-Zagreb strain (NCBI DNA accession 
number F266290). The T7 RNA polymerase promoter 
sequence was added to the 5’ end of the antigenomic cDNA 
and the hepatitis delta virus ribozyme and a T7 RNA 
polymerase terminator sequences were added to the 3’ end of 
the antigenomic cDNA. Sequence at nucleotides 5502 (Sca 
I) and 9343 (Mlu I) was modified to facilitate cDNA 
cloning. The three amino acid residues at positions 3682, 
3862 and 10555 (3682KR, 3862SN, 10555KR) that were 
different from the EZ vaccine strains were corrected by site-
directed mutagenesis. The MV antigenomic cDNA was 
cloned into pUC18 vector and denoted as pEZ (Fig. 1). 
Supporting plasmids encoding measles N, P and L genes 
were cloned into pCITE plasmids under the control of T7 
promoter as previously described and were designed pN, pP 
and pL respectively [30]. 
Fig. (1). Construction of measles vaccine vectors encoding ecto domains of RSV F and EBV gp350 and protein expression in virus-infected 
Vero cells. (A) RSV F ectodomain and EBV gp350 ectodomains were inserted in the 1
st and 3
rd transcription units of the measles Zagreb 
strain genome. Insertion was performed in the non-coding region 3' proximally of the MV N gene or between P and M genes of pEZ under 
the control of additional measles transcriptional units containing gene stop (GE)-gene start (GS) sequences. *RSV F gene (aa. 1-524) was 
inserted into EcoRV site using blunt ligation. 
#EBV gp350 full length (aa. 1-960), EBV gp350 truncated (aa. 1-470) or RSV F gene was 
inserted between EcoRV and AfeI site. (B) Vero cells were infected at an MOI of 3.0 with measles viruses encoding soluble RSV F (sF1 or 
sF3) or soluble EBV gp350 (gp350 or gp350 tr). After 18 h, western blots were used to detect presence of measles virus nucleoprotein in 
infected Vero cell lysates or RSV F protein, EBV gp350 protein in the supernatant. Black arrowheads indicate the predicted molecular 
masses of the proteins. Relative intensity of the MV N protein bands was expressed as the intensity of the band relative to the rEZ control. 
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  Construction of measles virus vectored antigenomic 
cDNA.  The ectodomain of RSV F and EBV gp350 
ectodomains were inserted into the non-coding region 3' 
proximal of the N gene or in the junction between the P and 
M genes of pEZ (Fig. 1). Each inserted gene contained 
measles virus transcriptional unit consisting of the sequences 
of N gene stop (GE-N) and P gene start (GS-P). To insert the 
RSV F gene into the promoter proximal location, a pUC-
SnaBI/SacII (pUC-S/S) subclone that contained the T7 
promoter and MV sequence of 1 to 2044 with a silent 
mutation at nt 821 to knockout EcoRV enzyme site was 
generated. A gene cassette containing the  ectodomain of 
RSV-F (aa 1-524) followed by GE-N and GS-P sequence 
were inserted into EcoRV site at nt 99. The genomic DNA 
was in multiples of 6 nucleotides (the rule of six). The SnaB 
I-Sac II fragment was swiped back to pEZ antigenomic 
cDNA (Fig. 1A) and the resulting cDNA was denoted as 
pEZ-RSVsF1. 
  To insert the RSV F gene and EBV gp350 gene into pEZ 
between the P and M genes, a pUC-SacII/NarI (pUC-S/N) 
subclone that contained the MV sequence of 2045 nt to 4924 
nt was constructed. A gene cassette containing gene end 
(GE) of N, gene start (GS) of P and ectodomain of RSV-F 
(aa 1-524), full length (aa 1 -861) or truncated (aa 1-470) 
ectodomain of gp350 at SpeI site (nt 3372). The Sac II to 
Nar I fragment was swiped back to pEZ antigenomic cDNA 
(Fig.  1A) and the resulting cDNA was denoted as pEZ-
RSVsF3, pEZ-EBVgp350 and pEZ-EBVgp350tr 
respectively. 
  Generation of recombinant measles virus and 
vectored measles viruses. Rescue of the recombinant 
viruses from MV antigenomic cDNA was performed as 
previously described [16, 30, 31]. Briefly, HEp-2 cells were 
infected with MVA-T7 at a multiplicity of infectivity (moi) 
of 5 for an hour prior to transfection. A DNA mixture of pEZ 
(0.8 μg), pN (0.4 μg), pP (0.4 μg) and pL (0.2 μg) were co-
transfected into MVA-T7 infected HEp-2 cells using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The culture 
medium was replaced with DMEM containing 2% FBS after 
overnight incubation at 37
oC. The transfected cells were 
incubated for an additional 3 to 4 days and the culture 
supernatant was used to infect fresh Vero cells to amplify the 
rescued virus. The rescued viruses were then plaque purified 
twice in Vero cells. The viruses rescued from pEZ, pEZ-
RSVsF1, pEZ-RSVsF3, pEZ-EBVgp350 and pEZ-
EBVgp350tr were designated as rEZ, sF1, sF3, gp350 and 
gp350tr, respectively. 
  Evaluation of recombinant measles viruses for their 
replication in cell cultures. Replication kinetics of rEZ, gp350, 
gp350tr, sF1 or sF3 viruses was compared in Vero cells. Vero 
cells in six-well plates were infected with each virus at a MOI of 
0.01 in triplicates. After a 1 hour adsorption at room 
temperature, the cells were washed three times with phosphate-
buffered saline (PBS) and incubated with 2 mL of complete 
DMEM at 35
oC with 5% CO2. Aliquots of culture supernatant 
were collected daily from each well for 7 days and stored at -
80
oC until virus titration. Viral titers were determined by plaque 
assay in Vero cells as previously described [32]. Replication 
kinetic was performed twice in triplicate and each supernatant 
sample was titered in duplicate. 
 Western  blot.  Vero cells were infected at a MOI of 3.0 
with rEZ, gp350, gp350tr, sF1 or sF3 for 18 hours at 37°C. 
Culture supernatant and cells were harvested separately. The 
cells were scraped and pelleted for 10 sec at 6,000 rpm in 
microfuge tubes and lysed in lysis buffer (50mM Tris-HCl, 
150 mM NaCl, 1% Triton X-100, 0.5% [vol/vol] protease 
inhibitor cocktail, pH 8.0) (Sigma, St. Louis, MO) for 10 
min on ice. The resulting cell lysates were cleared by 
centrifugation at 13,000 rpm for 5 min. 
  Proteins from culture supernatant or cell lysates were 
separated by electrophoresis and transferred onto a PVDF 
membrane. Viral proteins were detected with anti-measles 
nucleoprotein (clone 2D7, Santa Cruz Biotechnology), 
polyclonal rabbit EBV gp350 [33] or monoclonal antibody 
against RSV F proteins (palivizumab, MedImmune, 
Gaithersburg, MD) antibodies. Intensities of the bands were 
quantified by ImageQuant software (GE Healthcare, 
Piscataway, NJ). Relative intensity was determined by 
comparing pixel intensity of the band relative to the rEZ 
control. 
  Cotton rat studies. Specific-pathogen-free 6- to 8-week-
old cotton rats were purchased from Harlan (Indianapolis, 
IN). The animal study protocol was approved by 
MedImmune’s Institutional Animal Care and Use 
Committee. Animals were anesthetized with isoflurane by 
inhalation and vaccinated intramuscularly (i.m.) with 10
5 
PFU of rEZ, gp350tr, gp350, sF1 or sF3 in a 200 μl 
inoculum volume. The control groups were inoculated 
intramuscularly (i.m) with PBS, 10
5 PFU of UV-inactivated 
sF3, or intransally (i.n) with 10
6 PFU of RSV A2 strain. The 
animals were boosted with the same dose of viruses 4 weeks 
later. 
  The animals were observed for clinical signs daily and 
bled at 14-day intervals to measure antibody responses. 
Twenty-eight days after the second immunization, the cotton 
rats from measles virus vectored RSV vaccine groups were 
challenged with 10
6 PFU of RSV A2 strain i.n. The lungs 
were harvested on day 4 post-challenge and viral titers were 
determined by plaque assay. 
 Rhesus  macaque  study.  Adult rhesus macaques aged 3-
9 year-old were used for the immunogenicity study at Valley 
Biosystems (West Sacramento, CA). All experimental 
procedures were approved by the Institutional Animal Use 
and Care Committee at MedImmune and Valley Biosystems. 
Measles vaccine immunization history of the rhesus 
macaques was confirmed by neutralization assay prior to the 
study. A total of 16 rhesus macaques (8 measles virus sero-
positive, 8 naïve) were used in the study. Half of the animals 
(4 measles virus sero-positive, 4 naïve) received two doses 
of gp350 intramuscularly using 10
5 PFU/inoculation and the 
other half received two doses of sF3 at the same dose 
intramuscularly. The inoculations were performed at 4 week 
intervals. Blood was drawn from each animal every 14 days 
to assess immune responses. Animals were anesthetized with 
ketamine intramuscularly at each procedure. Clinical 
symptoms were monitored by veterinarians for the duration 
of the study. 
  EBV gp350 and RSV F protein-specific ELISA assay. 
EBV gp350- or RSV F-specific enzyme-linked immunosor-
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of gp350 or F protein-specific antibodies. Briefly, 100 ng of 
purified recombinant soluble EBV gp350 or RSV F protein 
expressed from mammalian cells was adsorbed onto 
Immulon 2B plates overnight in PBS at 4°C. The plate was 
blocked with 5% BSA in PBS. Serial dilutions of animal sera 
in PBS/1%BSA were added to the plate and incubated for an 
hour at room temperature. After washing, HRP-conjugated 
anti-cotton rat IgG (Immunology Consultants Laboratory, 
Newberg, OR) or anti-rhesus macaques IgG (Rockland 
Immunochemicals, Boyertown, PA) were added and 
incubated for 1 hour. Finally, the plate was developed with 
tetramethylbenzidine peroxidase substrate (KPL, Rockford, 
IL) and stopped with HCl. Absorbances of the samples were 
read at 450 nm and the titer for each sample was calculated 
by determining the dilution at which the absorbance reached 
2 times over the reading of no serum control. The lower 
limits of detection were 3.3 log2 and 6.6 log2 for EBV gp350 
ELISA and RSV F ELISA, respectively. 
 Neutralization assays. Measles virus specific 
neutralizing antibodies were determined as described 
previously [34] in 96-well plates using Vero cells. 
Neutralizing antibody titer is defined as the highest dilution 
that inhibits 50% CPE. RSV specific neutralizing antibody 
was determined by the plaque reduction neutralization assay 
as described previously [35]. The lower limit of detection 
was 4.3 log2 and 3.0 log2 for MV microneutralization and 
RSV plaque reduction assays, respectively. EBV specific 
neutralizing antibody titer was determined by the method 
described by Sashihara et al.,[36]. 
 ELISPOT  assay.  ELISpot assays were performed with 
spleens from vaccinated and control cotton rats 14 days after 
the second dose and peripheral blood mononucleocyte cells 
(PBMC) of rhesus monkeys 28 days after the second dose. 
Splenocytes were isolated as previously described [37]. 
Splenocytes were counted using Vi-Cell (Beckman Coulter, 
Brea, CA). Gamma interferon (IFN-) and Interleukin 4-
secreting T cells were quantified in an enzyme-linked 
immunospot (ELISpot) assay using R&D DuoSet ELISA 
System for cotton rat IFN- and IL-4 antibodies (R&D 
Systems, Minneapolis, MN) as previously described using 
10 μg/mL of EBV gp350 or RSV F proteins for stimulation 
[38]. Spots were scanned and counted by ImmunoSpot spot 
Analyzer (Cellular Technology, Cleveland, OH). The 
numbers of IFN- or IL-4 secreting cells were expressed as 
the number cells per 10
6 cells. 
 Statistics.  GraphPad Prism software was used to analyze 
the data (GraphPad Software Inc., San Diego, CA). All data 
were expressed as the mean and standard error. The data 
were also analyzed by Mann-Whitney rank sum test to 
compare data distribution between any two experimental 
groups. Titer comparison between viruses in replication 
kinetic experiment was performed using the Kruskal-Wallis 
test, assuming non-parametric distribution. 
RESULTS 
Cloning and Expression of RSV and EBV Antigens from 
Measles Virus 
  The reverse genetics system for measles Edmonston-
Zagreb (EZ) vaccine virus was established by transfecting   
 
MV antigenomic plasmid pEZ together with pP, pN and pL 
into MVA-T7 infected HEp-2 cells to recover infectious EZ 
virus. To generate rEZ expressing RSV F or EBV gp350, the 
F ectodomain of RSV and EBV gp350 were cloned into the 
MV antigenomic cDNA (Fig. 1A). The F was cloned at the 
two positions of the viral genome: one proximal to the N 
gene (1
st position) and the other between the P and M genes 
(3
rd position). EBV gp350 ectodomain and its N-terminal 
half of the gp350 (amino acid 1-470, gp350tr) that encoded 
the receptor binding site to CD21 [39] were also cloned into 
the EZ genome at the 1
st and 3
rd positions. Recombinant EZ 
with RSV F, EBV gp350 and EBV gp350tr inserted at the 1
st 
or 3
rd position were generated. However, viruses with gp350 
and gp350tr inserted at the 1
st position replicated poorly in 
vitro and were not evaluated further. The rescued 
recombinant viruses expressing RSV F or EBV gp350 or 
gp350tr were designed as sF1 (F at the 1
st position), sF3 (F at 
the 3
rd position), gp350 and gp350tr (both at the 3
rd position), 
respectively. 
  To confirm that these recombinant measles viruses 
expressed the desired antigens, the expression of the inserts 
in infected Vero cells was examined by Western blotting 
analysis. In addition to MV N protein that was detected in 
infected cell lysate (Fig. 1B), RSV F and EBV gp350 were 
detected in the culture supernatant of the infected cells (Fig. 
1B), indicating the production of secreted form of RSV F 
and EBVgp350 proteins from virus infected cells. The 
observation of lower MV N expression in Vero cells infected 
with sF1 compared to other viruses may be attributed to the 
insertion of RSV F proximal to the MV N gene, which 
moved the MV N gene to the 2
nd position of the genome and 
reduced its mRNA transcript level. The relative expression 
of RSV F to MV N, however, was shown to be higher for 
sF1 compared to sF3. This is consistent with the observation 
that genes proximal to 3’ end of the genome are transcribed 
more abundantly than those downstream and more RSV F 
was produced from sF1 than sF3 per virion. 
  Viral replication efficiency of these recombinant viruses 
was assessed by growth kinetics in Vero cells. Both 
recombinant EZ (rEZ) and EZ vaccine viruses grew to a 
peak titer of 7.9 log10 PFU/mL on day 5 (Fig. 3A). rEZ with 
either RSVF (Fig. 2A) or EBVgp350 (Fig. 2B) inserts had 
comparable growth kinetics but slightly lower (between 0.1-
0.7 log10 lower) than rEZ. The peak titers between the 
viruses were not statistically different. sF3 had a faster 
growth kinetics and reached peak titer on day 3 instead of 
day 5. Therefore, insertion of RSV F or EBV gp350 into the 
genome of EZ did not significantly reduce viral growth in 
vitro. 
Evaluation of Antibody Response in Cotton Rats 
  Cotton rats had previously been demonstrated to be semi-
permissive to measles virus infection [40] and are the best 
available small animal model for MV infection. In addition, 
cotton rats are susceptible to RSV infection and have been 
used in the evaluation of RSV vaccines [41, 42] and anti-
RSV antibody investigated for prophylactic application [43]. 
The ability of rEZ vectored vaccines to induce humoral 
responses to measles virus and RSV F or EBV gp350 protein 
were assessed in cotton rats. Cotton rats were immunized   
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Fig. (2). Growth kinetics of measles vectors encoding soluble RSV F or soluble EBV gp350 was similar to that of recombinant 
measles constructs. Vero cells were infected at MOI of 0.01 with measles vectors. Cells were incubated at 35
oC for 7 days. Cells and 
supernatant were sampled daily for virus titers using standard plaque assay. * denotes statistically significant difference in titer of sF3 versus 
sF1, rEZ and EZ using the Kruskal-Wallis test. 
Fig. (3). RSV F-specific and EBV gp350-specific splenocytes were induced in the spleens of cotton rats immunized i.m. with measles 
vectors. Cotton rats were vaccinated on days 0 and 28 with measles vectors. Splenocytes were harvested 7 days after the second measles 
vectors vaccination. A total of 3 x 10
5 cells were stimulated with either RSV F protein (A and C) or EBV gp350 protein (B and D) in vitro 
for 20 h, and the numbers of IFN- spot-forming cells (A and B) and IL-4 spot-forming cells (C and D) were quantified by an ELISPOT 
assay. Spots were counted with an automated counting device and are expressed as numbers of spots per 10
6 cells. Groups are compared 
using Mann-Whitney rank sum test. Each symbol represents an individual animal. 
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with two doses of rEZ viruses intramuscularly at 4 weeks 
interval. Sera were collected 4 weeks post dose 1 and 2 
weeks post dose 2. Measles virus neutralizing antibodies 
(MV Ab) were induced rapidly after one dose 
administration, reaching titers of 6.3-8.7 log2. No significant 
differences in MV Ab titers were observed among the 
animals receiving sF1, sF3, gp350 or gp350tr compared to 
rEZ. The 2
nd dose increased MV Ab titers by 2-4 folds 
(Table  1). The control animals vaccinated with UV-
inactivated sF3 or RSV A2 virus did not have detectable MV 
Ab titer (data not shown). 
  RSV-specific antibody responses were measured by RSV 
F-specific ELISA and microneutralization assay. sF1 or sF3 
induced RSV F-specific IgG antibody in the vaccinated 
cotton rats (about 15.5-15.9 log2 post dose 1 and 22.1-23.7 
log2 post dose 2). The RSV F-specific IgG antibody titers 
were similar between the sF1 and sF3 vaccinated groups. 
RSV neutralizing antibody titers were also measured against 
RSV A2 strain. After the first dose, sF1 and sF3 induced 
RSV neutralizing Ab and titers were boosted to 7.5-log2 and 
8.9-log2 after the second dose (Table 1). There was no 
statistical difference in antibody response between sF1 and 
sF3 vaccinated animals and those intranasally infected with 2 
doses of RSV A2 strain (9.4 log2 ± 1.5, data not shown). 
Animals vaccinated with UV-inactivated sF3 did not have 
detectable RSV antibody (data not shown), indicating that 
virus immunogenicity was dependent on live virus infection. 
  EBV-specific antibody response was measured by EBV 
gp350-specific ELISA assay. EBV specific ELISA Ab 
response was detected after one dose administrations of 
gp350 or gp350tr; after the 2
nd dose the titers reached 7.3 and 
4.3 log2 for gp350 and gp350tr vaccinated animals, 
respectively (Table 1). Gp350 induced a significantly higher 
EBV gp350-specific IgG titer than gp350tr. EBV specific 
neutralizing antibody could not be detected by the EBV 
neutralization assay. 
Evaluation of Cell Mediated Immune Response in 
Vaccinated Cotton Rats 
  Cell mediated immune response is important for viral 
clearance and may play an important role in vaccine 
mediated protective immune response [44]. RSV F-specific 
and EBV gp350-specific T cell responses in splenocytes 
were examined by IFN- and IL-4 ELISpot on day 7 post the 
2
nd dose. The frequencies of RSV F-specific IFN- secreting 
cells were statistically higher in sF3 vaccinated group 
(average 130 spots/10
6 splenocytes) compared to sF1 
vaccinated (average 9 spots/10
6 splenocytes) or RSV A2-
infected animals (average 45 spots/10
6 splenocytes) (Fig. 
3A). The RSV F-specific IL-4 secreting cells were low, 
averaged about 20 spots/10
6 splenocytes for both sF1 and 
sF3 groups. Surprisingly, no RSV-specific IL-4 secreting 
cells detected in RSV A2-infected animals (Fig. 3C). Thus, 
sF3 and RSV induced a Th1-biased response based on the 
higher IFN- to IL-4 secreting cell ratio. 
  The frequencies of EBV gp350-specific IFN- and IL-4 
secreting cells for gp350 (average 23 spots and 15 spots/10
6 
splenocytes for IFN- and IL-4 respectively) and gp350tr 
vaccinated groups (average 49 spots and 41 spots/10
6 
splenocytes for IFN- and IL-4 respectively) were not 
statistically different, but were statistically higher than the 
PBS control group for the gp350tr group (Fig. 3B, D). 
Protection Against RSV A2 Challenge in sF1 and sF3 
Vaccinated Cotton Rats 
  Animal model is not available for assessing EBV vaccine 
induced protective immune response. Cotton rat is the best 
available small animal model to evaluate RSV vaccine 
induced protection against wt RSV challenge infection. To 
assess if the immune responses induced from sF1 and sF3 
could provide protection against RSV A2 challenge, 
vaccinated cotton rats were challenged with RSV A2 
intranasally and virus titers in the lungs were measured. 
Similar to RSV infected animals, sF1 or sF3 offered 
complete protection against RSV A2 challenge with viral 
titers in the lungs that was at least 4.5 log10 lower than the 
control animals. In contrast, cotton rats vaccinated with 10
5 
PFU of UV-inactivated sF3 had viral titer similar to the PBS 
control group, indicating that viral replication is necessary 
for induction of protective immune response (Fig. 4). 
Immunogenicity of EZ Vectored Vaccines in Rhesus 
Macaques 
  Rhesus macaques are fully permissive to measles virus 
infection and have been used for evaluation of measles 
Table 1.  Antibody response of cotton rats to rEZ vectored gp350 and RSV F 
 
 MV  Neutralizing Ab (Mean log2 ± SD Titer)
b,e  EBV-gp350 or RSV-F ELISA Ab  
(Mean log2 ± SD Titers)
c,e 
RSV or EBV Neutralizing Ab  
(Mean log2 ± SD Titer)
d,e 
Inoculation  Dose 1
a Dose  2
a  Dose 1  Dose 2  Dose 1  Dose 2 
rEZ 8.4  + 0.4  10.1 + 0.9  < 3.3   < 3.3  < 3.3  < 3.3 
gp350 8.7  + 0.6  11.0+ 0.7  3.3 + 0.1  7.3 + 0.3  < 3.3  < 3.3 
gp350tr 8.2  + 0.2  10.2 + 0.8  3.3 + 0.1  4.3 + 0.1  < 3.3  < 3.3 
rEZ 7.1  + 0.4  8.7 + 0.6  < 6.6  < 6.6  < 3.0  < 3.0 
sF1 6.7  + 0.5  8.7 + 0.9  15.9 + 2.7  23.7 + 1.2  5.4 + 0.7  7.5 + 1.0 
sF3 6.3  + 0.0  8.7 + 1.1  15.5 + 0.9  22.1 + 0.8  4.2 + 1.0  8.9 + 1.1 
aSerum samples were measured 4 weeks post dose 1 and 2 weeks post dose 2. 
bTiter is defined as log2 reciprocal dilution of serum that inhibited cytopathic effects in 50% of the wells containing measles infected Vero cells. 
cTiter is defined as log2 of the highest dilution of serum that gave OD450 reading 2x of the background. 
dRSV titer is defined as log2 reciprocal dilution of serum that reduced plaques on HEp-2 cells by 50%. 
eTiter on day 0 for all assays were under the limit of detection. 18    The Open Virology Journal, 2012, Volume 6  Mok et al. 
vaccine and measles virus pathogenesis studies [45-47]. The 
ability of rEZ vectored RSV F and EBV gp350 to induce 
measles virus specific or F or gp350 specific immune 
responses was examined in this more permissive animal 
model. Since sF3 demonstrated better immunogenicity than 
sF1 in cotton rats, only sF3 was evaluated in measles virus 
seropositive (MV+) rhesus macaques that had prior measles 
vaccination and measles virus seronegative (MV-) rhesus 
macaques. No abnormal clinical signs were observed and 
serum chemistries were within the normal range in all 
monkeys throughout the study (data not shown). sF3 or 
gp350 vaccinated monkeys induced a similar level of MV 
neutralizing antibody in both MV- and MV+ monkeys. A 
second dose of vaccination with sF3 or gp350 increased MV 
neutralizing Ab titers by about 4-fold in all groups (Table 2). 
The Ab titer differences between the groups were not 
statistically significant. 
 
Fig. (4). Reduction of titers of RSV in the lungs of cotton rats 
vaccinated with measles-vectored RSV F after challenge. Naïve 
cotton rats were immunized with 10
5 PFU of sF1 or sF3 on day 0 
and 28. Cotton rats were then challenged with 10
6 PFU of RSV A2 
on day 56. Lungs were harvested on day 60 and RSV titers were 
determined in the lung homogenates by standard plaque assay. Each 
experimental group represents 5 individual animals except in UV-
inactivated sF3 group (n=3). 
  Antibody responses to the inserted genes, however, were 
relatively low. sF3 inoculated animals had RSV F-specific IgG 
titer higher than the pre-vaccination level (titers were under the 
detection limit). F specific IgG Ab titers were 9.3 log2 and 8.8 
log2 in MV+ and MV- groups after dose 1, respectively. After a 
second dose, three out of 4 animals in MV+ group had more 
than 4-fold increase in RSV F-specific IgG Ab titer but none of 
the animals in MV- group had 4-fold increase in Ab response 
(Fig. 5A). After two doses of vaccination, RSV neutralizing Ab 
titers in all groups were very low in both MV+ and MV- groups. 
Seven out of 8 animals had a detectable level of RSV 
neutralizing Ab. The RSV Nt Ab titers were not statistically 
different between the two groups (5.0 log2 for MV+ versus 4.5 
log2 for MV- groups) (Table 2). Ab responses to EBV gp350 in 
the gp350 vaccinated monkeys were not detected at all time 
points. Similar to antibody responses, IFN- secreting cells in 
PBMC to measles viral antigens were significantly higher (~10-
fold) than the responses to either RSV F or EBV gp350 (Fig. 
5B) while PBMC, when stimulated with measles viral antigens, 
RSV F or EBV gp350, did not secrete any IL-4. Thus, 
compared to the cotton rat studies, rEZ vectored viruses were 
poorly immunogenic in the primate model. 
DISCUSSION 
  Reverse genetics has been developed for generating 
recombinant measles virus vectored vaccines encoding 
foreign antigens based on the Edmonston-Schwarz and AIK-
C vaccine strain [15, 48]. The reverse genetic system 
described in this study was based on the EZ vaccine strain, 
which is used predominantly outside the US. The EZ strain 
might be immunogenic in population that has prior measles 
vaccine immunization [23]. The ectodomains of the RSV F 
and EBV gp350 glycoproteins instead of full length proteins 
were engineered to be expressed by EZ to avoid the 
incorporation of the foreign surface glycoproteins onto the 
measles virus envelope. The expression of heterologous 
membrane proteins on measles virus surface may alter the 
binding of measles to its natural receptors and thus change 
the tissue tropism of measles virus. We showed that both 
RSV F and EBV gp350 was expressed efficiently in vitro. 
However, rEZ vectored vaccines induced insert specific 
responses in cotton rats but poor responses in rhesus 
macaques although both cotton rats and rhesus macaques 
have previously been shown to be permissive to measles 
virus infection to various degrees [47, 49-51]. 
Table 2.  Antibody Response of Rhesus Macaques to rEZ Vectored gp350 or F 
 
MV Neutralizing Ab  
(mean log2 ± SD Titer) 
RSV or EBV ELISA Ab 
(Mean log2 ± SD Titer) 
RSV or EBV  Neutralizing Ab  
(Mean log2 ± SD Titer)
c  Inoculation  Prior MV 
Vaccination
a 
Day 0  Dose 1
b Dose  2
b  Dose 1  Dose 2  Dose 1  Dose 2 
gp350 +  4.3  + 1.2  5.7 + 0.5  7.3 + 0.6  < 3.3  < 3.3  < 3.3  < 3.3 
gp350 -  <  3.3  5.4  + 1.1  7.3 + 0.1  < 3.3  < 3.3  < 3.3  < 3.3 
sF3 +  4.2  + 0.7  5.2 + 1.5  7.5 + 1.2  9.3 + 1.9  11.8 + 1.0  3.3 + 0.5  5.0 + 0.8 
sF3 - <  3.3  5.9  + 1.1  7.9 + 1.1  8.8 + 1.8  9.5 + 2.1  3.3 + 0.5  4.5 + 1.7 
aPreviously vaccinated with Measles vaccine. 
bSerum samples were measured 4 weeks post dose 1 and 2 weeks post dose 2. 
cRSV antibody titer is defined as log2 reciprocal dilution of serum that reduced plaques on HEp-2 cells by 50%; neutralization assay was performed with 10% guinea pig 
complement. 
Titers of prevaccinated animals were under the limit of detection in all the assays. 
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  One of the important determinants for inducing a robust 
immune response in vivo is the amount of the expressed 
antigen level and antigen presentation. We have evaluated 
the effect of the gene insertion location and antigen 
expression level because transcription of nonsegmented 
negative strand RNA viruses is obligatorily sequential [52]. 
The genes located at proximal to the 3’ promoter are 
produced more abundantly than the ones distal to the 
promoter [53]. Indeed, when RSV F was introduced 3’ 
proximally to the N gene, it produced 10 times more secreted 
RSV F protein than when inserted between the P and M 
junction (data not shown). In comparison, insertion of the 
gp350 of EBV at the 1st position of EZ significantly affected 
virus replication. Insertion of the EBV gp350 gene between 
the P and M genes had less effect on virus growth, similar to 
that shown for Hepatitis B surface antigen (HBsAg) (14). 
The gene insertion position affected immunogenicity of EZ 
vectored vaccines in cotton rats. rEZ encoding RSV F 
ectodomain induced antibody response against measles and 
RSV F. rEZ-sF3 induced MV specific antibody response 
comparable to rEZ and RSV specific Ab response 
comparable to those induced by intranasal RSV infection in 
cotton rats; it also induced cell mediated response as 
measured by IFN- ELISpot assay. Surprisingly, sF1 was 
inferior to sF3 in its ability to induce both RSV neutralizing 
antibody and RSV F-specific IFN- secreting T cell 
responses, suggesting that sF1 may be more attenuated than 
sF3  in vivo. Immune response is dependent on viral 
infectivity and the nature of the inserts. rEZ vectored EBV 
gp350 and gp350tr induced lower gp350 specific IgG Ab 
response and undetectable neutralizing antibody response in 
cotton rats. 
  The cotton rats immunized with MV expressing RSV F 
were also challenged with wt RSV. After challenge, the 
number of IFN- secreting cells was higher than IL-4 
secreting cells, which was consistent with a Th1-biased 
response (data not shown). RSV enhanced disease has been 
associated with FI-RSV vaccine [54, 55]. A chimeric 
parainfluenza virus vectored RSV F [35] did not cause 
enhanced disease in hamsters and has been proven to be safe 
in phase I clinical trial in seronegative children [56]. 
Recently, a report from another group has shown that 
measles virus vectored RSV F did not cause unusual 
pathology in cotton rats after RSV challenge, thus, the 
likelihood of the MV vector F to cause enhanced disease is 
very low [15]. 
  Since cotton rats are partially permissive to MV, MV 
vectored vaccine was further evaluated in rhesus macaques. 
Rhesus macaque is fully permissive to measles virus 
infection and the infected monkeys develop symptoms 
similar to those experienced by humans, such as skin rash, 
fever and conjunctivitis [47]. This monkey model was used 
in the neurovirulence testing of MV vaccine [57]. In 
addition, since rhesus macaques could be infected with 
human measles virus, the breeding colony is commonly 
vaccinated with MV. This allowed us to examine the effect 
of prior vaccination on vectored measles and mimic our 
target populations that either have maternal antibodies or 
have measles vaccination history. rEZ and rEZ expressing 
gp350 and sF3 induced a good level of antibody response to 
 
Fig. (5). RSV F specific antibody response and cellular response in rhesus macques vaccinated with measles vectors. Measles sero-
negative and sero-positive rhesus macaques were immunized with 10
5 PFU of sF3 or gp350 on day 0 and 28. (A) RSV F titers were 
measured on day 28 (post dose 1) and 42 (post dose 2) using ELISA. (B) PBMCs were isolated from whole blood on day 56. The numbers of 
IFN- spot forming cells were quantified with an ELISpot assay when PBMCs were stimulated with measles viral antigens, RSV F or EBV 
gp350 antigens in vitro. Spots were counted with an automated counting device and are expressed as numbers of spots per 10
6 cells ± SEM. 
ND = not determined. 
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measles virus irrespective of their sero-status to MV. The 
antibody response was slightly lower in magnitude than what 
were observed in the cotton rats as the dose per kg used in 
the rhesus was ~ 90 times lower than in cotton rats. The 
antibody response to the F and gp350 inserts was much 
lower in rhesus macaques. A previous report showed that 
two doses of MV-HIV gp140 at 5x10
6 TCID50 (25 times 
higher dose than our study) induced a robust Ab response 
towards HIV gp140 in monkeys [10]. However, three doses 
of 10
4 TCID50 (1/15 our dose) of MV vectored HBV surface 
antigen induced a very low response in monkeys [14]. Thus, 
the low humoral responses to the vectored inserts in rhesus 
macaques may be due to a lower dose used in this study. 
  Measles vaccine virus has been shown to bind signaling 
lymphocyte activation molecule (SLAM; also known as 
CD150) on activated immune cells and CD46 [58], which is 
ubiquitously expressed on human cells. It is thought that 
virus infects the respiratory tract through SLAM on dendritic 
cells. In cotton rats, although human CD46 and CD150 
homologs have not been reported [59], measles virus could 
replicate in the lungs of these animals after intranasal 
infection [40]. We have evaluated different routes of 
administration (both intranasal and intramuscular) of MV 
vectored RSV F in cotton rats and found that both 
inoculation routes offered protection against RSV challenge 
after immunization (data not shown). Rhesus macaques 
possess both CD46 and CD150 receptor homologs [60] and 
are susceptible to measles virus infection and develop 
diseases similar to humans. The difference in receptors 
between the two animal species may be able to explain why 
insertion of the insert into EZ strain have further attenuated 
viruses and reduced immunogenicity of the virus in rhesus 
macaques but not in cotton rats. 
  We also examined replication of EZ vectored RSV F and 
EBV gp350 in vivo by using real time qRT-PCR since 
differential in growth kinetics of recombinant measles virus 
may explain the difference in antibody responses. However, 
we were not able to detect measles genomes in PBMC 
isolated from whole blood 24 hours post vaccination. This 
may be attributed to the low copies of measles virus 
circulating in the blood or the time point used to measure 
measles kinetics in vivo was not optimal. In conjunction, we 
have examined replication of EZ vectors in PBMC of rhesus 
macaques  ex vivo to determine if insertion of the foreign 
gene affected replication of these viruses in PBMC. PHA-
activated PBMC cells were infected with rMV at MOI of 1.0 
and growth kinetics were determined for 7 days. The peak 
titer of the recombinant viruses containing RSV F or EBV 
gp350 were only 0.5 log10 lower than rEZ (data not shown), 
indicating the vectored vaccine could infect rhesus cells. We 
also investigated genetic stability of the insert by serially 
passaging the recombinant viruses in Vero cells 10 times and 
did not find the loss of the inserted gene expression as 
reported previously [61, 62]. 
  Other negative stranded RNA viruses including 
Newcastle disease virus (NDV), vesicular stomatitis virus, 
Sendai virus and parainfluenza viruses [35, 63-65] had been 
evaluated as vectors to deliver foreign antigens and were 
shown to elicit both humoral and cellular responses in non-
human primates and to confer protection to virus challenge 
in some cases [63, 66-69]. The vectored vaccines were 
normally delivered to non-human primates by either 
intranasal or intratracheal inoculation route. We found 
intranasal and intramuscular vaccination of EZ induced 
similar antibody response in cotton rats. It is possible that 
intranasal immunization might be more immunogenic than 
intramuscular vaccination in monkeys. 
  Based on our study, MV vector is probably not suitable 
for delivery of the EBV gp350 antigen. Immunogenicity of 
adjuvanted gp350 protein vaccine has been demonstrated in 
young adults [29], adjvanted gp350 might be the right 
approach for EBV vaccine development. The amount of 
gp350 delivered by MV is likely not sufficient to induce 
gp350 specific immune response. The F protein of RSV 
delivered by MV is more immunogenic than EBV gp350, 
however, additional evaluation of immunogenicity of MV-
RSV F must be conduced before proceeding to testing this 
vaccine in humans. 
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